Search

Your search keyword '"Seo, Sang-Soo"' showing total 207 results
Start Over Author "Seo, Sang-Soo" Publication Year Range Last 10 years
207 results on '"Seo, Sang-Soo"'

4. The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer.

Author

Kim, Ji Hyun, Shin, Jun-Young, Park, Seog-Yun, Seo, Sang-Soo, Kang, Sokbom, Yoo, Chong Woo, Park, Sang-Yoon, and Lim, Myong Cheol

Subjects
NUCLEOTIDE sequencing, HOMOLOGOUS recombination, SOMATIC mutation, OVARIAN epithelial cancer, GENETIC testing, FALLOPIAN tubes
Abstract

The somatic BRCA1 or BRCA2 Pathogenic Variant (PV)/Likely PV (LPV) from Next Generation Sequencing (NGS) is the most important biomarker for PARP inhibitor use and maintenance-targeted therapies. A discrepancy in the detection rates of BRCA1 and BRCA2 PV/LPV was identified among the NGS platforms. The objective of this study was to compare the somatic BRCA results from two distinct platforms using the same cohort and to identify the causes of these differences. Patients with epithelial ovarian cancer who concurrently underwent tumor NGS using two different platforms between January 2022 and June 2023 were included in this study. The two platforms used were in-house tumor NGS (Illumina NextSeq 550Dx, SureSelectXT library kit, and datasets from 1000 Genomes, ESP6500, ExAC, and ClinVar) and GreenPlan homologous recombination deficiency (HRD) test (Illumina NextSeq 550Dx, customized Twist Bioscience library kit, and datasets from COSMIC and OncoKB). The results of somatic mutations in BRCA1 and BRCA2 were compared between the two platforms. Of the 118 patients, 11.9% (n = 14) exhibited a discordant interpretation of BRCA1 or BRCA2 between the two platforms. Eleven patients (9.3%) exhibited negative results in the in-house platform but positive results (eight seven as PV of BRCA1, one as PV of BRCA2, one as LPV of BRCA1, and two as LPV of BRCA2) in the GreenPlan HRD test, while three patients (2.6%) had positive BRCA pathogenic variants (two as PV of BRCA1 [c.3340G > T, c.5152 + 3 A > C], one as LPV of BRCA2 [c.8174G > T], and one as LPV of BRCA1 [c.5017_5019delCAC]) in the in-house platform but a negative result in the GreenPlan HRD test. The discordance rate of somatic BRCA1 or BRCA2 mutations from different platforms was approximately 12%. In the case of the strong implication of BRCA PV/LPV with a negative result with one genetic test, different platforms could be considered in limited cases. Careful interpretation and further studies for the cross-validation of gene analysis platforms are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae

Author

Lim, Myong Cheol, Won, Young-Joo, Lim, Jiwon, Seo, Sang-Soo, Kang, Sokbom, Yoo, Chong Woo, Kim, Joo-Young, Oh, Jae Hwan, Bristow, Robert E, and Park, Sang-Yoon

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rehabilitation, Colo-Rectal Cancer, Uterine Cancer, Clinical Research, Digestive Diseases, Prevention, Cancer, Adult, Aged, Aged, 80 and over, Colon, Colorectal Neoplasms, Comorbidity, Endometrial Neoplasms, Female, Humans, Incidence, Middle Aged, Neoplasms, Second Primary, Rectum, Registries, Republic of Korea, Survival Analysis, Survivors, Second primary tumor, Endometrial cancer, Colon cancer, Hereditary, Korea, Lynch syndrome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeTo evaluate the incidence of colon cancer as a second primary cancer (CCSPC) and the survival outcomes of women with and without CCSPC after the diagnosis of endometrial cancer (EC).MethodsThe standardized incidence ratio (SIR) of CCSPC and survival outcomes of EC survivors with and without CCSPC were analyzed using data from January 1 1993 to December 31 2011, obtained from the Korea Central Cancer Registry.ResultsOf 14,797 EC survivors, 147 (0.99%) developed CCSPC after an average interval of 5.5 years. The SIR of CCSPC among EC survivors was 2.56, higher than that of colon cancer in the general population. The SIR of CCSPC was highest for the ascending (3.77), followed by the transverse (3.45), descending colon (2.06), and rectum (1.99). The risk of a proximal site of CCSPC was high, especially within 5 years after the diagnosis of EC in the ascending (SIR, 4.37) and transverse (4.91) colon, and in young survivors (

Published
2018

6. Molecular mechanisms of neuronal homoeostasis in vivo

Author

Seo, Sang soo, Nolan, Matthew, and Hardingham, Giles

Subjects
612.8, fluorescent activated cell sorting, FACs, RNAseq, homeostasis, hippocampus
Abstract

Homeostatic plasticity is important in neurobiology for stabilising neuronal networks in the face of Hebbian forms of synaptic plasticity that are thought to mediate memory storage. Impairment of homeostatic plasticity has also been implicated in neurological diseases such as Rett syndrome and fragile X syndrome. Homeostatic plasticity can be achieved through scaling of the strength of synaptic connections between neurones or by changes in intrinsic excitability. While homeostatic plasticity has been studied mainly using in vitro preparations, it is for the most part not known whether changes of neural activity in vivo induce homeostatic changes. The molecular pathway responsible for homeostatic plasticity still remains unclear. In this thesis, I have used stereotaxic surgery to over express Kir2.1, an inwardly rectifying potassium channel, in vivo in the brains of adult mice. I show that the expression of Kir2.1 through adeno-associated virus (AAV) does not cause any adverse effects in the dentate gyrus nor the CA1 of the mouse hippocampus. I go on to use slice patch clamp methods to measure the change in electrical properties of granule cells in the dentate gyrus and pyramidal cells in CA1 caused by expression of Kir2.1. I show that the excitability of neurones expressing Kir2.1 was reduced compared to control neurones. By 2 weeks after virus injection the neurones showed homeostatic plasticity in response to Kir2.1 over expression. Interestingly, the mechanism of adaptation was different in different types of cells; dentate gyrus granule cells adapted through change in their intrinsic excitability, whereas CA1 pyramidal cells adapted by modifying the strength of their synaptic inputs. To establish whether induction of homeostatic plasticity is associated with changes in gene expression I used fluorescent activated cell sorting (FACs) to isolate pure population of neurones infected with viruses. I then sequenced RNA extracted from neurones expressing Kir2.1 and control neurones. Analysis of the RNAseq data revealed molecular candidates involved in homeostatic plasticity. In summary, I show that Kir2.1 over expression causes change in excitability and subsequent homeostatic plasticity in vivo. The mechanism of adaptation differs between cell types. RNAseq results identify novel candidates for future investigation.

Published
2016

7. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Author

Youn, Jin Won, Hur, Soo-Young, Woo, Jung Won, Kim, Yong-Man, Lim, Myong Cheol, Park, Sang Yoon, Seo, Sang Soo, No, Jae Hong, Kim, Byoung-Gie, Lee, Jae-Kwan, Shin, So Jin, Kim, Kyungun, Chaney, Marya F, Choi, Yoon-Jeong, Suh, You Suk, Park, Jong Sup, and Sung, Young Chul

Published
2020
Full Text
View/download PDF

16. Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial

Author

Kim, Jin Hee, Kim, Joo-Young, Yoon, Mee Sun, Kim, Young Seok, Lee, Jong Hoon, Kim, Hak Jae, Kim, Hunjung, Kim, Yeon-Joo, Yoo, Chong Woo, Nam, Byung-Ho, Kim, Tae Hyun, Kim, Suk-Ki, Kim, Sun Ho, Kang, Seokbom, Seo, Sang Soo, Lim, Myong Cheol, and Park, Sang-Yoon

Published
2016
Full Text
View/download PDF

18. Rationale and study design of the KOV-HIPEC-02 trial: a randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer

Author

Kim, Ji Hyun, primary, Park, Eun Young, additional, Kang, Sokbom, additional, Seo, Sang Soo, additional, Park, Sang Yoon, additional, Jeong, Dae Hoon, additional, Lee, Yoo-Young, additional, Choi, Chel Hoon, additional, Kim, Tae Joong, additional, Kim, Byoung-Gie, additional, Kim, Jae-Weon, additional, Chung, Hyun Hoon, additional, Kim, Tae Hun, additional, Lee, Taek Sang, additional, Lee, Shin Hwa, additional, Park, Jeong-Yeol, additional, Lee, Sung Jong, additional, Nam, Eun Ji, additional, Lee, Jung-Yun, additional, Jeon, Seob, additional, Kim, Ki Hyung, additional, Ha, Hyeongin, additional, Ko, Youngbok, additional, Lee, San-Hui, additional, Paik, Jong Chul, additional, Chang, Suk-Joon, additional, and Lim, Myong Cheol, additional

Published
2023
Full Text
View/download PDF

29. Randomized multicenter phase II trial of prophylactic irradiation of para‐aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group ( KROG 07‐01) study

Author

Yoon, Meesun, primary, Lee, Hyo Kyung, additional, Park, Eun Young, additional, Kim, Jin Hee, additional, Lee, Jong Hoon, additional, Kim, Young Seok, additional, Kim, Hak Jae, additional, Kim, Hunjung, additional, Yoo, Chong Woo, additional, Lee, Sun, additional, Hong, Eun Kyung, additional, Kim, Tae Hyun, additional, Kim, Tae‐Sung, additional, Seo, Sang‐soo, additional, Kang, Sokbom, additional, Chang, Suk‐Joon, additional, Shin, Hye Jin, additional, Uong, Tung Nguyen Thanh, additional, Lee, Semin, additional, and Kim, Joo‐Young, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results